title: Targeting the IFN-γ/CXCL10 pathway in lichen planus.
abstract: Lichen planus is a chronic inflammatory disease of the skin, mucous membranes and nails. Management of oral involvement, particularly atrophic and erosive lesions, is challenging. Noteworthy, there is a lack of published evidence for treatment. Cell-mediated cytotoxicity is actually regarded as a major mechanism of pathogenesis. The interferon-gamma induced chemokines CXCL10 and CXCL9 are strongly expressed in serum of patients as well as in both skin and mucosal lesions. Therefore the interferon gamma/CXCL10 axis is considered a key process for both progression and maintenance of chronic cytotoxic inflammation. According to these findings, the interferon gamma/CXCL10 axis could be considered a therapeutically attractive target to reverse inflammation. Since interferon gamma signal transduction occurs through JAK 1 and 2, JAK inhibitors could lead to blockade of interferon gamma signaling and downstream CXCL10 expression.
authors.affiliation: Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy. Electronic address: vito.dilernia@asmn.re.it.
authors.forename: Vito
authors.initials: V
authors.lastname: Di Lernia
mesh_terms: D054357:Chemokine CXCL10 / Q000378:metabolism*; D054370:Chemokine CXCL9 / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation; D007371:Interferon-gamma / Q000378:metabolism*; D008010:Lichen Planus / Q000628:therapy*; D008962:Models, Theoretical; D010880:Piperidines / Q000627:therapeutic use; D011401:Promoter Regions, Genetic; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D012867:Skin / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: C114753:CXCL10 protein, human; C080810:CXCL9 protein, human; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D004791:Enzyme Inhibitors; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; D007371:Interferon-gamma; C479163:tofacitinib